B. Riley reiterates buy on Journey Medical, cuts target
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
B. Riley Financial reaffirmed its "buy" rating on Journey Medical (NASDAQ:DERM) while lowering its price target to Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context